- Home
- XBIT vs TCRX Comparison
XBIT vs TCRX Comparison
Compare XBIT & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XBIT
- TCRX
- Stock Information
- Founded
- XBIT 2005
- TCRX 2018
- Country
- XBIT United States
- TCRX United States
- Employees
- XBIT N/A
- TCRX N/A
- Industry
- XBIT Pharmaceuticals and Biotechnology
- TCRX Biotechnology: Pharmaceutical Preparations
- Sector
- XBIT Health Care
- TCRX Health Care
- Exchange
- XBIT Nasdaq
- TCRX Nasdaq
- Market Cap
- XBIT 105.2M
- TCRX 90.5M
- IPO Year
- XBIT 2015
- TCRX 2021
- Fundamental
- Price
- XBIT $2.85
- TCRX $1.45
- Analyst Decision
- XBIT
- TCRX Strong Buy
- Analyst Count
- XBIT 0
- TCRX 6
- Target Price
- XBIT N/A
- TCRX $9.50
- AVG Volume (30 Days)
- XBIT 47.1K
- TCRX 774.8K
- Earning Date
- XBIT 05-14-2025
- TCRX 05-06-2025
- Dividend Yield
- XBIT N/A
- TCRX N/A
- EPS Growth
- XBIT N/A
- TCRX N/A
- EPS
- XBIT N/A
- TCRX N/A
- Revenue
- XBIT N/A
- TCRX $4,421,000.00
- Revenue This Year
- XBIT N/A
- TCRX $68.86
- Revenue Next Year
- XBIT N/A
- TCRX $14.01
- P/E Ratio
- XBIT N/A
- TCRX N/A
- Revenue Growth
- XBIT N/A
- TCRX N/A
- 52 Week Low
- XBIT $2.65
- TCRX $1.02
- 52 Week High
- XBIT $8.32
- TCRX $9.29
- Technical
- Relative Strength Index (RSI)
- XBIT 45.38
- TCRX 49.42
- Support Level
- XBIT $2.71
- TCRX $1.33
- Resistance Level
- XBIT $2.98
- TCRX $1.49
- Average True Range (ATR)
- XBIT 0.13
- TCRX 0.11
- MACD
- XBIT 0.00
- TCRX 0.02
- Stochastic Oscillator
- XBIT 23.81
- TCRX 69.12
About XBIT XBiotech Inc.
XBiotech Inc is a United States-based clinical-stage biopharmaceutical company. It is engaged in discovering and developing True Human (antibody technology) monoclonal antibodies for treating a variety of diseases. The company focuses on developing Anti-IL-1 a therapeutic antibody as a treatment for cancer. Geographically, all of its operations are in the United States.
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.